Serves as the physician within oncology clinical programme teams for lung and head/neck cancers, leading medical monitoring, safety oversight and clinical data interpretation. Partners with the Senior Scientist and cross-functional teams on protocol development, regulatory interactions and investigator engagement, with on-site presence 2-3 days per week.
Serves as the physician within oncology clinical programme teams for lung and head/neck cancers, leading medical monitoring, safety oversight and clinical data interpretation across Phase I–III studies. Partners with Senior Scientists and cross-functional matrix teams on protocol development, regulatory interactions and investigator engagement, with on-site presence 2–3 days per week.
Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late pre-candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work across small molecules, biologics and antibody drug conjugates, applying AI/ML and quantitative systems pharmacology methods. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.
Leads model-informed drug development for oncology programs, defining and executing model-based strategies from late discovery through lifecycle management. Conducts population PK, exposure-response, simulation-based trial design and dose selection, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis. Presents to governance boards and regulators and works across matrix teams on small molecules, biologics and antibody drug conjugates.
Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within Oncology Translational Medicine's Clinical Pharmacology Modelling and Simulation group, working across small molecules, biologics and antibody drug conjugates.
Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis to small molecules, biologics and antibody drug conjugates. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.
Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work across small molecules, biologics and antibody drug conjugates, applying AI/ML and quantitative systems pharmacology methods. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.
Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within a matrixed Clinical Pharmacology Modelling and Simulation group working across small molecules, biologics and antibody drug conjugates.
Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and works with cross-functional partners in digital medicine, translational imaging and systems modelling. Based in the newly established Clinical Pharmacology and Quantitative Medicine organisation.
Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and works with digital medicine, imaging, modelling and data science partners. Reports into the Respiratory, Immunology & Inflammation Research Unit.
Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and works with digital medicine, translational imaging and modelling specialists. Based in Stevenage with a planned relocation to Cambridge, UK by early 2029.
Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and partners with digital medicine, translational imaging, biostatistics and AI/ML teams. Reports into the Respiratory, Immunology & Inflammation Research Unit within the new Clinical Pharmacology and Quantitative Medicine organisation.
Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Drafts regulatory content for FDA, EMA, CDE, PMDA and ICH submissions, and partners with digital medicine, translational imaging, modelling and data science teams to embed quantitative approaches into asset-level decisions.
Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Sits in the Clinical Pharmacology and Quantitative Medicine organisation, partnering with digital medicine, translational imaging, modelling and data science teams, and drafting regulatory content for FDA, EMA and ICH submissions.
Lead end-to-end application of Model-Informed Drug Development across the drug development lifecycle, from first-in-human studies through filing and lifecycle management, providing clinical pharmacology strategy and evidence generation. Draft and review regulatory content for FDA, EMA, CDE, PMDA and ICH, and build cross-functional partnerships across digital medicine, translational imaging, AI/ML and biostatistics. The role sits in the newly established Clinical Pharmacology and Quantitative Medicine organisation, reporting into the Respiratory, Immunology & Inflammation Research Unit.
